Alperen AKSAKAL, Leyla SAĞLAM, Buğra KERGET, Elif YILMAZEL UÇAR

Comparison of the effectiveness of high-flow and conventional nasal cannula oxygen therapy in pulmonary embolism patients with acute hypoxemic respiratory failure

Comparison of the effectiveness of high-flow and conventional nasal cannula oxygen therapy in pulmonary embolism patients with acute hypoxemic respiratory failure Introduction: The leading cause of mortality in pulmonary embolism (PE) is hypoxemic respiratory failure. The aim of this study was to compare the efficacy of high-flow nasal cannula (HFNC) and conventional nasal cannula (CNC) oxygen therapy in PE patients with hypoxemia. Materials and Methods: Fifty-eight patients with a PaO2/FIO2 ratio below 300 who were admitted to the emergency department with acute respiratory distress and followed up in our intensive care unit due to PE between March and October 2019 were included in the study. One group (n= 29) received HFNC oxygen therapy and the other group (n= 29) received CNC oxygen therapy. Results: Arterial blood gas analysis showed no significant differences in baseline SpO2 and PaO2 between the HFNC and CNC groups, whereas both values were significantly higher in the HFNC group starting at 1 hour (PaO2: p= .01, p= .001, p= .001; SpO2: p= .009, p= .005, p= .002). Among massive PE patients with contraindications for thrombolytic therapy, there was no significant difference between the HFNC and CNC groups in baseline SpO2, PaO2, or respiratory rate, but those who received HFNC therapy had significant higher SpO2 starting at 15 minutes (p= .004 for all), significantly higher PaO2 starting at 1 hour (p= .01, p= .001, p= .001), and significantly lower respiratory rate starting at 30 minutes (p= .003, p= .001, p= .001, p= .002, p= .002). Conclusion: In patients presenting with PE and hypoxemic respiratory failure, HFNC oxygen therapy was more effective on both vital signs and arterial blood gas parameters compared to conventional oxygen therapy and can be used safely as primary treatment

PDF

___

1. Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. The Lancet 2016; 388(10063): 3060-73.

2. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. The Lancet 2012; 379(9828): 1835-46.

3. Colebatch H, Olsen C, Nadel J. Effect of histamine, serotonin, and acetylcholine on the peripheral airways. J Appl Physiol 1966; 21(1): 217-26.

4. Bräunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth H-J, Wirtz H. Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration 2013; 85(4): 319-25.

5. Nishimura M. High-flow nasal cannula oxygen therapy in adults. J int Care 2015; 3(1): 15.

6. Yilmazel Ucar E, Araz Ö, Kerget B, Akgun M, Saglam L. Comparison of high‐flow and conventional nasal cannula oxygen in patients undergoing endobronchial ultrasonography. Int Med J 2020 Aug 3.

7. Zhao H, Wang H, Sun F, Lyu S, An Y. High-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy but not to noninvasive mechanical ventilation on intubation rate: a systematic review and meta-analysis. Crit Care 2017; 21(1): 184.

8. Force ADT, Ranieri V, Rubenfeld G, Thompson B, Ferguson N, Caldwell E. Acute respiratory distress syndrome. Jama 2012; 307(23): 2526-33.

9. Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of pulmonary embolism: an update. JAm Coll Cardio 2016; 67(8): 976-90.

10. Moore AJ, Wachsmann J, Chamarthy MR, Panjikaran L, Tanabe Y, Rajiah P. Imaging of acute pulmonary embolism: an update. Cardiovasc Diagn Ther 2018; 8(3): 225.

11. Stone HH, Nemir Jr P. Study of the role of 5-hydroxytryptamine (serotonin) and histamine in the pathogenesis of pulmonary embolism in man. Ann Surgery 1960; 152(5): 890.

12. Delcroix M, Melot C, Vermeulen F, Naeije R. Hypoxic pulmonary vasoconstriction and gas exchange in acute canine pulmonary embolism. J Appl Physiol 1996; 80(4): 1240-8.

13. Kerget B, Afşin DE, Aksakal A, Aşkin S, Araz Ö. Could HIF1α be a novel biomarker for the clinical course and treatment of pulmonary embolism? Turk J Med Sci 2020: 50.

14. Subramanian M, Ramadurai S, Arthur P, Gopalan S. Hypoxia as an independent predictor of adverse outcomes in pulmonary embolism. Asian Cardiovasc Thoracic Ann 2018; 26(1): 38-43.

15. Roca O, Hernández G, Díaz-Lobato S, Carratalá JM, Gutiérrez RM, Masclans JR. Current evidence for the effectiveness of heated and humidified high flow nasal cannula supportive therapy in adult patients with respiratory failure. Crit care 2016; 20(1): 109.

16. Jones PG, Kamona S, Doran O, Sawtell F, Wilsher M. Randomized controlled trial of humidified high-flow nasal oxygen for acute respiratory distress in the emergency department: the HOT-ER study. Resp care 2016; 61(3): 291-9.

17. Messika J, Goutorbe P, Hajage D, Ricard J-D. Severe pulmonary embolism managed with high-flow nasal cannula oxygen therapy. European J Emerg Med 2017; 24(3): 230- 2.

18. Spadaro S, Stripoli T, Volta CA, Trerotoli P, Pierucci P, Staffieri F, et al. High-flow nasal cannula oxygen therapy decreases postextubation neuroventilatory drive and work of breathing in patients with chronic obstructive pulmonary disease. Crit Care 2018; 22(1): 180.

19. Leung C, Joynt G, Gomersall C, Wong W, Lee A, Ling L, et al. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. J Hosp Infect 2019; 101(1): 84-7.

20. Makdee O, Monsomboon A, Surabenjawong U, Praphruetkit N, Chaisirin W, Chakorn T, et al. High-flow nasal cannula versus conventional oxygen therapy in emergency department patients with cardiogenic pulmonary edema: a randomized controlled trial. Ann Emerg Med 2017; 70(4): 465-72. e2.